- Previous Close
3.9700 - Open
3.9700 - Bid 3.6500 x 100
- Ask 3.8700 x 100
- Day's Range
3.6500 - 4.0450 - 52 Week Range
2.4200 - 15.7000 - Volume
76,299 - Avg. Volume
492,747 - Market Cap (intraday)
2.745M - Beta (5Y Monthly) 0.71
- PE Ratio (TTM)
0.02 - EPS (TTM)
230.4000 - Earnings Date Feb 11, 2025 - Feb 17, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, which is a small molecule compound acting as a selective dual CB1 /CB2 agonist; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
www.inmedpharma.comRecent News: INM
View MorePerformance Overview: INM
Trailing total returns as of 1/28/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INM
View MoreValuation Measures
Market Cap
2.87M
Enterprise Value
-1.65M
Trailing P/E
0.02
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.31
Price/Book (mrq)
0.34
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-166.94%
Return on Assets (ttm)
-39.22%
Return on Equity (ttm)
-72.08%
Revenue (ttm)
4.6M
Net Income Avi to Common (ttm)
-7.68M
Diluted EPS (ttm)
230.4000
Balance Sheet and Cash Flow
Total Cash (mrq)
6.61M
Total Debt/Equity (mrq)
10.46%
Levered Free Cash Flow (ttm)
-4.02M